PT1885363E - Utilização de 3,1-1b-cis-di-hidrotetrabenazina para o tratamento dos sintomas da doença de huntington - Google Patents
Utilização de 3,1-1b-cis-di-hidrotetrabenazina para o tratamento dos sintomas da doença de huntington Download PDFInfo
- Publication number
- PT1885363E PT1885363E PT06764942T PT06764942T PT1885363E PT 1885363 E PT1885363 E PT 1885363E PT 06764942 T PT06764942 T PT 06764942T PT 06764942 T PT06764942 T PT 06764942T PT 1885363 E PT1885363 E PT 1885363E
- Authority
- PT
- Portugal
- Prior art keywords
- dihydrotetrabenazine
- huntington
- cis
- symptoms
- disease
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010008748 Chorea Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000015592 Involuntary movements Diseases 0.000 abstract 1
- 206010028347 Muscle twitching Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 208000012601 choreatic disease Diseases 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000005021 gait Effects 0.000 abstract 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514501.6A GB0514501D0 (en) | 2005-07-14 | 2005-07-14 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1885363E true PT1885363E (pt) | 2009-01-08 |
Family
ID=34897233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06764942T PT1885363E (pt) | 2005-07-14 | 2006-07-13 | Utilização de 3,1-1b-cis-di-hidrotetrabenazina para o tratamento dos sintomas da doença de huntington |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20080319000A1 (enExample) |
| EP (2) | EP1885363B1 (enExample) |
| JP (1) | JP2009501202A (enExample) |
| KR (1) | KR20080030666A (enExample) |
| CN (1) | CN101282726A (enExample) |
| AT (2) | ATE522215T1 (enExample) |
| AU (1) | AU2006268098B2 (enExample) |
| CA (1) | CA2615077A1 (enExample) |
| CY (1) | CY1108653T1 (enExample) |
| DE (1) | DE602006002982D1 (enExample) |
| DK (1) | DK1885363T3 (enExample) |
| ES (1) | ES2314931T3 (enExample) |
| GB (1) | GB0514501D0 (enExample) |
| HR (1) | HRP20080677T3 (enExample) |
| ME (1) | ME01629B (enExample) |
| NZ (1) | NZ565522A (enExample) |
| PL (1) | PL1885363T3 (enExample) |
| PT (1) | PT1885363E (enExample) |
| RS (1) | RS50626B (enExample) |
| RU (1) | RU2409365C2 (enExample) |
| SI (1) | SI1885363T1 (enExample) |
| WO (1) | WO2007007105A1 (enExample) |
| ZA (1) | ZA200800905B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| GB0516168D0 (en) * | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| GB0810857D0 (en) * | 2008-06-13 | 2008-07-23 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| US20120208773A1 (en) * | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2463451A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012095548A2 (es) | 2011-01-13 | 2012-07-19 | Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) | Compuestos para el tratamiento de enfermedades neurodegenerativas |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| RU2768738C2 (ru) * | 2017-04-01 | 2022-03-24 | Адептио Фармасьютикалз Лимитед | ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ |
| DK3784237T3 (da) | 2018-04-25 | 2024-01-08 | Shinkei Therapeutics Inc | Indretning til transdermal levering af tetrabenazin |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| JP2022541021A (ja) * | 2019-07-16 | 2022-09-21 | ラッシュ・ユニバーシティ・メディカル・センター | 神経変性障害を治療するためのベンゾエート含有組成物の使用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US2954382A (en) * | 1960-09-27 | Xpreparation of hexahydrobenzoquinol- | ||
| US3095419A (en) * | 1963-06-25 | Process for preparing z-oxo-j- | ||
| US3314966A (en) * | 1967-04-18 | Substituted benzo[a]quinolizines | ||
| US3132147A (en) * | 1964-05-05 | |||
| US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| US3123609A (en) * | 1964-03-03 | Benzo | ||
| US3009918A (en) * | 1961-11-21 | Chz ch | ||
| US3159638A (en) * | 1964-12-01 | Xcha-chj | ||
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US3079395A (en) * | 1963-02-26 | Novel z-oxq-benzoquinoliaine | ||
| US3053845A (en) * | 1962-09-11 | Benzofykedocolines | ||
| US3045021A (en) * | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
| GB999092A (en) * | 1959-11-24 | 1965-07-21 | Wellcome Found | Method for making benzo(a)-quinolizine derivatives |
| US3375254A (en) * | 1961-09-29 | 1968-03-26 | Burroughs Wellcome Co | Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines |
| US3105079A (en) * | 1961-12-29 | 1963-09-24 | Pfizer & Co C | 10-aminobenzopyridocolines |
| US3390152A (en) * | 1965-10-21 | 1968-06-25 | Abbott Lab | 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines |
| JPS4836303B1 (enExample) * | 1968-12-27 | 1973-11-02 | ||
| US3635986A (en) * | 1969-12-22 | 1972-01-18 | Miles Lab | 2-substituted amino-hexahydrobenzo(a)quinolizines |
| YU264675A (en) * | 1974-10-23 | 1982-05-31 | Chinoin Gyogyszer Es Vegyeszet | Process for obtaining benzo (a)-quinolizidine derivatives |
| GB1513824A (en) * | 1975-05-22 | 1978-06-14 | Wyeth John & Brother Ltd | 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative |
| US4133812A (en) * | 1975-11-21 | 1979-01-09 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Process for producing benzo (a) quinolizine derivatives |
| US4304913A (en) * | 1978-11-20 | 1981-12-08 | Miles Laboratories, Inc. | Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines |
| US4353656A (en) * | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| EP0211595B1 (en) * | 1985-07-30 | 1991-11-13 | Glaxo Group Limited | Devices for administering medicaments to patients |
| GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US6087376A (en) * | 1997-02-05 | 2000-07-11 | University Of Kentucky Research Foundation | Use of lobeline compounds in the treatment of central nervous system diseases and pathologies |
| FR2794742B1 (fr) * | 1999-06-11 | 2005-06-03 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
| US6632666B2 (en) * | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| CA2673334C (en) * | 2003-06-16 | 2013-11-12 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) * | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| KR100682506B1 (ko) * | 2005-01-18 | 2007-02-15 | (주)젠크로스 | 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물 |
| GB0516168D0 (en) * | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| GB2463451A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
-
2005
- 2005-07-14 GB GBGB0514501.6A patent/GB0514501D0/en not_active Ceased
-
2006
- 2006-05-31 ME MEP-2008-916A patent/ME01629B/me unknown
- 2006-07-13 KR KR1020087003481A patent/KR20080030666A/ko not_active Withdrawn
- 2006-07-13 ES ES06764942T patent/ES2314931T3/es active Active
- 2006-07-13 CN CNA2006800339758A patent/CN101282726A/zh active Pending
- 2006-07-13 PL PL06764942T patent/PL1885363T3/pl unknown
- 2006-07-13 DE DE602006002982T patent/DE602006002982D1/de active Active
- 2006-07-13 EP EP06764942A patent/EP1885363B1/en active Active
- 2006-07-13 AT AT08017191T patent/ATE522215T1/de not_active IP Right Cessation
- 2006-07-13 ZA ZA200800905A patent/ZA200800905B/xx unknown
- 2006-07-13 DK DK06764942T patent/DK1885363T3/da active
- 2006-07-13 SI SI200630147T patent/SI1885363T1/sl unknown
- 2006-07-13 AT AT06764942T patent/ATE409481T1/de active
- 2006-07-13 AU AU2006268098A patent/AU2006268098B2/en not_active Ceased
- 2006-07-13 PT PT06764942T patent/PT1885363E/pt unknown
- 2006-07-13 RS RSP-2008/0492A patent/RS50626B/sr unknown
- 2006-07-13 NZ NZ565522A patent/NZ565522A/en not_active IP Right Cessation
- 2006-07-13 EP EP08017191A patent/EP2027861B1/en active Active
- 2006-07-13 CA CA002615077A patent/CA2615077A1/en not_active Abandoned
- 2006-07-13 HR HR20080677T patent/HRP20080677T3/xx unknown
- 2006-07-13 WO PCT/GB2006/002593 patent/WO2007007105A1/en not_active Ceased
- 2006-07-13 RU RU2008105590/15A patent/RU2409365C2/ru not_active IP Right Cessation
- 2006-07-13 JP JP2008520952A patent/JP2009501202A/ja active Pending
- 2006-07-13 US US11/995,436 patent/US20080319000A1/en not_active Abandoned
-
2008
- 2008-12-22 CY CY20081101475T patent/CY1108653T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1885363T1 (sl) | 2009-02-28 |
| CN101282726A (zh) | 2008-10-08 |
| GB0514501D0 (en) | 2005-08-24 |
| ATE409481T1 (de) | 2008-10-15 |
| ES2314931T3 (es) | 2009-03-16 |
| RS50626B (sr) | 2010-06-30 |
| CY1108653T1 (el) | 2014-04-09 |
| EP2027861A1 (en) | 2009-02-25 |
| RU2409365C2 (ru) | 2011-01-20 |
| PL1885363T3 (pl) | 2009-05-29 |
| EP2027861B1 (en) | 2011-08-31 |
| RU2008105590A (ru) | 2009-08-20 |
| AU2006268098B2 (en) | 2011-02-17 |
| NZ565522A (en) | 2010-04-30 |
| ME01629B (me) | 2010-06-30 |
| HRP20080677T3 (hr) | 2009-02-28 |
| DK1885363T3 (da) | 2008-12-08 |
| US20080319000A1 (en) | 2008-12-25 |
| WO2007007105A1 (en) | 2007-01-18 |
| AU2006268098A1 (en) | 2007-01-18 |
| EP1885363B1 (en) | 2008-10-01 |
| ATE522215T1 (de) | 2011-09-15 |
| DE602006002982D1 (de) | 2008-11-13 |
| JP2009501202A (ja) | 2009-01-15 |
| KR20080030666A (ko) | 2008-04-04 |
| ZA200800905B (en) | 2010-04-28 |
| CA2615077A1 (en) | 2007-01-18 |
| HK1111085A1 (en) | 2008-08-01 |
| EP1885363A1 (en) | 2008-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200800905B (en) | Use of 3,11B-CIS-Dihydrotetrabenazine for the treatment of symptoms of huntington's disease | |
| ZA200703110B (en) | Compounds, compositions and methods of inhibiting α-synuclein toxicity | |
| WO2006091693A3 (en) | Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor | |
| WO2008150490A3 (en) | Uses and compositions for treatment of psoriasis and crohn's disease | |
| IL176393A0 (en) | Patterned laser treatment of the retina | |
| IL177015B (en) | Isolated human rpe cells and their use for the treatment of retinal degenerative diseases | |
| ES2414872T8 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
| IL190150A0 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease | |
| WO2007012061A3 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
| ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
| EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
| IL189104A (en) | Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders. | |
| UA94580C2 (ru) | Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием | |
| GB0410399D0 (en) | The treatment of respiratory disease | |
| WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
| GB0410398D0 (en) | The treatment of respiratory disease | |
| GB0521716D0 (en) | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases | |
| WO2005118592A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
| ZA200703992B (en) | 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | |
| MY140538A (en) | Substituted n-acyl-2-aminothiazoles | |
| DK1732648T3 (da) | Sygdomsbehandling | |
| IL191208A (en) | Use of phenofibrate or its derivative for the preparation of a drug for the treatment of diabetic retinopathy | |
| RU2002103738A (ru) | Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний | |
| HK1110080A (en) | Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy |